Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | HMGCR | P04035 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GGT1 | P19440 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16542592 | 0.88 | TSHR (0.38) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL85014 | 0.87 | TSHR (0.42) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL12066145 | 0.86 | TSHR (0.36) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL21600741 | 0.86 | TSHR (0.43) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL24760401 | 0.86 | TET2 (0.38) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL13316716 | 0.84 | ALDH1A1 (0.47) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL20635493 | 0.84 | TSHR (0.35) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL24093686 | 0.84 | TSHR (0.35) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL9977958 | 0.82 | ALDH1A1 (0.38) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL12890724 | 0.82 | TSHR (0.48) | TSHRALDH1A1CYP2D6CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3645505-B1 | PROCESS FOR THE SEPARATION OF LONG CHAIN AMINO ACIDS AND DIBASIC ACIDS | VITAWORKS IP LLC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2024-02-29 | — | — | US | disclosed |
| WO-2023186661-A1 | ELECTROCHEMICAL OXIDATION OF CYCLOALKENES AND CYCLOALKANES INTO α,ω-DICARBOXYLIC ACIDS OR INTO KETOCARBOXYLIC ACIDS AND CYCLOALKANONE COMPOUNDS | EVONIK OPERATIONS GMBH (DE) | 2023-10-05 | — | — | WO | disclosed |
| EP-4253605-A1 | ELECTROCHEMICAL OXIDATION OF CYCLOALKENES TO ALPHA, OMEGA-DICARBOXYLIC ACIDS AND KETOCARBOXYLIC ACIDS | Evonik Operations GmbH (DE) | 2023-10-04 | — | — | EP | disclosed |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | NOVARTIS AG (CH) | 2023-09-12 | — | — | US | disclosed |
| EP-3645502-B1 | PROCESS FOR THE SEPARATION OF LONG CHAIN AMINO ACIDS AND DIBASIC ACIDS | VITAWORKS IP LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11685757-B2 | Pharmaceutical co-crystal composition and use thereof | Syn-Nat Products Enterprise LLC (US) | 2023-06-27 | — | — | US | disclosed |
| EP-3589623-B1 | PRODUCTION OF 2,5-FURANDICARBOXYLIC ACID | TNO (NL) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-3652149-B1 | PROCESS FOR PRODUCING LONG CHAIN ACIDS AND DIBASIC ACIDS | VITAWORKS IP LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20090221684-A1 | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| WO-2009027706-A2 | CANCER IMAGING AND TREATMENT | Technische Universität München (DE) | 2009-03-05 | — | — | WO | disclosed |
| WO-2008006064-A2 | BIOMIMETIC POLYMERS AND USES THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007076231-A2 | BRIDGED PHENOL-HETEROCYCLIC LIGANDS, METAL COMPLEXES, AND THEIR USES AS CATALYSTS | SYMYX TECHNOLOGIES, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070111037-A1 | ALIPHATIC POLYESTERS AND LUBRICANTS CONTAINING THE POLYESTERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2007-05-17 | — | — | US | disclosed |
| US-5301087-A | Electrolyte for electrolytic capacitor and electrolytic capacitor using the same | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1994-04-05 | — | — | US | disclosed |
| EP-0501439-A1 | Electrolyte for electrolytic capacitor and electrolytic capacitor using the same | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1992-09-02 | — | — | EP | disclosed |
| EP-0120257-B1 | PROCESS FOR THE PREPARATION OF ISOCHROMAN DERIVATIVES | HAARMANN & REIMER GMBH (DE) | 1986-12-17 | — | — | EP | disclosed |
| EP-0120257-A1 | Process for the preparation of isochroman derivatives | HAARMANN & REIMER GMBH (DE) | 1984-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066132-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | TSHR 828/4885ALDH1A1 849/4885CYP2D6 2119/4885 |
| US-11685757-B2 | Pharmaceutical co-crystal composition and use thereof | CXCR3, CCR3, CCR5 | TSHR 3538/4885ALDH1A1 4196/4885CYP2D6 837/4885 |
| US-11752211-B2 | Fatty acids and their use in conjugation to biomolecules | FABP1, FABP2, FABP3 | TSHR 620/4885ALDH1A1 907/4885CYP2D6 1688/4885 |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | TSHR 2801/4885ALDH1A1 3407/4885CYP2D6 4061/4885 |
| US-20090221684-A1 | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof | ANXA6, STING1, ADM2 | TSHR 3726/4885ALDH1A1 2863/4885CYP2D6 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.